Chiara Corti, MD
@ccortimd.bsky.social
MD • Breast Medical Oncologist from @IEOufficiale • Research Fellow @DFCI_BreastOnc • Editor @PLOSDigiHealth • Epistemic diversity enthusiast. • #FirstGen • Rock lover 🎸
Pinned
Chiara Corti, MD
@ccortimd.bsky.social
· Nov 19
“We need #women who are so strong they can be #gentle, so #educated they can be #humble, so fierce they can be #compassionate, so #passionate they can be #rational, and so disciplined they can be #free.”
― Kavita N. Ramdas
― Kavita N. Ramdas
🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social
www.asco.org/abstracts-pr...
www.asco.org/abstracts-pr...
Differential genomic landscape of estrogen receptor (ER)-low versus ER-positive (ER+) and ER-negative (ER-) metastatic breast cancer (MBC). - ASCO
www.asco.org
May 29, 2025 at 10:54 PM
🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social
www.asco.org/abstracts-pr...
www.asco.org/abstracts-pr...
Try and play with it. All the feedback will be welcomed by
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!
ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!
ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.
🚨New from ASCO: The ASCO Guidelines Assistant, a new generative AI tool developed in collaboration with Google Cloud, more quickly connects ASCO members with timely and trustworthy information. #ASCO25
Learn more: brnw.ch/21wSP18
Learn more: brnw.ch/21wSP18
May 21, 2025 at 8:35 PM
Try and play with it. All the feedback will be welcomed by
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!
ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!
ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.
🚨NEW @ascocancer.bsky.social #EduBook chapter:
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm
Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
The art of sequencing therapy in the management of breast cancer is a multifaceted
challenge that demands the careful integration of clinical trial data, real-world
evidence, and individualized patien...
shorturl.at
May 15, 2025 at 10:21 PM
🚨NEW @ascocancer.bsky.social #EduBook chapter:
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm
In medio stat virtus
Right in time for #AACR25: two insightful commentaries this week on the topics of critical thinking and critiquing science and #clinicaltrials results. It can be done with respect, and we need that type of objectivity more than ever
jamanetwork.com/journals/jam...
www.ejcancer.com/article/S095...
jamanetwork.com/journals/jam...
www.ejcancer.com/article/S095...
April 25, 2025 at 2:49 AM
In medio stat virtus
Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs.
@Nature article explains the game:
“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”
www.nature.com/articles/d41...
@Nature article explains the game:
“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”
www.nature.com/articles/d41...
Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue
Study finds dozens of journals that have hiked their fees and started churning out papers after being acquired by small, recently formed companies.
www.nature.com
April 23, 2025 at 12:55 PM
Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs.
@Nature article explains the game:
“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”
www.nature.com/articles/d41...
@Nature article explains the game:
“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”
www.nature.com/articles/d41...
“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”
April 22, 2025 at 5:56 PM
“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”
Reposted by Chiara Corti, MD
Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
April 15, 2025 at 7:31 PM
Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer
Reposted by Chiara Corti, MD
www.sciencedirect.com/science/arti...
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.
Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Artificial intelligence (AI) s…
www.sciencedirect.com
April 12, 2025 at 1:59 AM
www.sciencedirect.com/science/arti...
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.
"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .
April 12, 2025 at 9:30 PM
"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .
From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social
April 6, 2025 at 4:48 PM
From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social
Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org
March 26, 2025 at 11:08 PM
Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org
AI-generated content floods literature with poor-quality publications, casts doubt on metrics,
@science.org and Retraction Watch investigation finds.
www.science.org/content/arti...
@science.org and Retraction Watch investigation finds.
www.science.org/content/arti...
Shoddy commentaries—a quick and dirty route to higher impact numbers—are on the rise
AI-generated content floods literature with poor-quality publications, casts doubt on metrics, Science and Retraction Watch investigation finds
www.science.org
January 5, 2025 at 7:44 PM
AI-generated content floods literature with poor-quality publications, casts doubt on metrics,
@science.org and Retraction Watch investigation finds.
www.science.org/content/arti...
@science.org and Retraction Watch investigation finds.
www.science.org/content/arti...
Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️
December 24, 2024 at 8:02 PM
Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️
🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm
shorturl.at/AXNdm
shorturl.at/AXNdm
Breakthrough law offers cancer patients in New York relief for 'scalp-cooling therapy'
New York has become the first state in the country to require insurance coverage for what's called "scalp-cooling therapy," which can reduce hair loss for chemo patients.
shorturl.at
December 23, 2024 at 3:07 AM
🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm
shorturl.at/AXNdm
shorturl.at/AXNdm
Reposted by Chiara Corti, MD
Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression.
Biopsy remains critical.
#sabcs24 @oncbrothers.bsky.social
Biopsy remains critical.
#sabcs24 @oncbrothers.bsky.social
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
#SABCS2024 @sabcs.bsky.social
December 13, 2024 at 2:19 PM
Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression.
Biopsy remains critical.
#sabcs24 @oncbrothers.bsky.social
Biopsy remains critical.
#sabcs24 @oncbrothers.bsky.social
Reposted by Chiara Corti, MD
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
December 13, 2024 at 3:57 PM
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Join us in Row 10 to see our poster on outcomes in HER2+ & TNBC pts treated with neoadjuvant tx!
Key findings:
✅ pCR linked to better outcomes
✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx
✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events)
#SABCS24 #bcsm
Key findings:
✅ pCR linked to better outcomes
✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx
✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events)
#SABCS24 #bcsm
December 13, 2024 at 6:32 PM
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
#SABCS2024 @sabcs.bsky.social
December 13, 2024 at 6:05 AM
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
#SABCS2024 @sabcs.bsky.social
Reposted by Chiara Corti, MD
Don’t miss #SABCS24 Clinical Controversies Session on: Omission of Axillary Staging in ER-Positive #BreastCancer - Implications on Adjuvant Therapies, where Dr. Elizabeth Mittendorf will discuss the current data.
December 11, 2024 at 6:55 PM
Don’t miss #SABCS24 Clinical Controversies Session on: Omission of Axillary Staging in ER-Positive #BreastCancer - Implications on Adjuvant Therapies, where Dr. Elizabeth Mittendorf will discuss the current data.
Please join us for the poster session today at 12.30PM! Our work on patients who experienced recurrence on adjuvant abemaciclib is in Row 9, right in front of the exhibitors. We look forward to chatting with you! @sabcs.bsky.social @dfcibreastonc.bsky.social
December 11, 2024 at 6:34 PM
Please join us for the poster session today at 12.30PM! Our work on patients who experienced recurrence on adjuvant abemaciclib is in Row 9, right in front of the exhibitors. We look forward to chatting with you! @sabcs.bsky.social @dfcibreastonc.bsky.social
Reposted by Chiara Corti, MD
Meet Chiara Corti, MD(@ccortimd.bsky.social)! She came to Dana-Farber from IEO and the Università degli Studi di Milano. Now a #DFCIAdvancedFellow her research focuses on optimizing #BreastCancer treatment via tumor & microenvironment profiling and leveraging AI to streamline clinical operations.
December 11, 2024 at 3:23 PM
Meet Chiara Corti, MD(@ccortimd.bsky.social)! She came to Dana-Farber from IEO and the Università degli Studi di Milano. Now a #DFCIAdvancedFellow her research focuses on optimizing #BreastCancer treatment via tumor & microenvironment profiling and leveraging AI to streamline clinical operations.
Reposted by Chiara Corti, MD
Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive
High TMB showed a signal for pembro benefit, but only in 8% of pts
Predictive biomarkers for ICI in early TNBC are urgently needed!
@oncoalert.bsky.social
High TMB showed a signal for pembro benefit, but only in 8% of pts
Predictive biomarkers for ICI in early TNBC are urgently needed!
@oncoalert.bsky.social
December 11, 2024 at 1:28 AM
Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive
High TMB showed a signal for pembro benefit, but only in 8% of pts
Predictive biomarkers for ICI in early TNBC are urgently needed!
@oncoalert.bsky.social
High TMB showed a signal for pembro benefit, but only in 8% of pts
Predictive biomarkers for ICI in early TNBC are urgently needed!
@oncoalert.bsky.social
Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social
December 11, 2024 at 12:15 AM
Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social
Reposted by Chiara Corti, MD
Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰
May explain why parity and age impacts breast cancer risk 📊.
Early pregnancy ⬇️ breast cancer risk by 30-40%
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
May explain why parity and age impacts breast cancer risk 📊.
Early pregnancy ⬇️ breast cancer risk by 30-40%
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
December 10, 2024 at 10:19 PM
Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰
May explain why parity and age impacts breast cancer risk 📊.
Early pregnancy ⬇️ breast cancer risk by 30-40%
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
May explain why parity and age impacts breast cancer risk 📊.
Early pregnancy ⬇️ breast cancer risk by 30-40%
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Reposted by Chiara Corti, MD
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
December 6, 2024 at 8:24 PM
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us: